C2N Diagnostics Receives FDA 510(k) Clearance for Alzheimer's Blood Test

C2N Diagnostics has received FDA 510(k) clearance for its PrecivityAD2 blood test that detects Alzheimer's disease, enabling wider clinical adoption in the United States.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 3 sources have reported it.